- Home
- REGN vs MU Comparison
REGN vs MU Comparison
Compare REGN & MU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- MU
- Stock Information
- Founded
- REGN 1988
- MU 1978
- Country
- REGN United States
- MU United States
- Employees
- REGN N/A
- MU N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- MU Semiconductors
- Sector
- REGN Health Care
- MU Technology
- Exchange
- REGN Nasdaq
- MU Nasdaq
- Market Cap
- REGN 110.0B
- MU 107.9B
- IPO Year
- REGN 1991
- MU N/A
- Fundamental
- Price
- REGN $738.00
- MU $102.64
- Analyst Decision
- REGN Buy
- MU Strong Buy
- Analyst Count
- REGN 24
- MU 26
- Target Price
- REGN $1,110.63
- MU $146.28
- AVG Volume (30 Days)
- REGN 887.5K
- MU 15.6M
- Earning Date
- REGN 10-31-2024
- MU 12-18-2024
- Dividend Yield
- REGN N/A
- MU 0.45%
- EPS Growth
- REGN 15.31
- MU N/A
- EPS
- REGN 40.43
- MU 0.70
- Revenue
- REGN $13,847,100,000.00
- MU $25,111,000,000.00
- Revenue This Year
- REGN $10.13
- MU $56.72
- Revenue Next Year
- REGN $4.00
- MU $19.66
- P/E Ratio
- REGN $18.25
- MU $146.63
- Revenue Growth
- REGN 5.72
- MU 61.59
- 52 Week Low
- REGN $735.95
- MU $72.93
- 52 Week High
- REGN $1,211.20
- MU $157.54
- Technical
- Relative Strength Index (RSI)
- REGN 13.13
- MU 49.55
- Support Level
- REGN $735.95
- MU $95.53
- Resistance Level
- REGN $757.56
- MU $114.30
- Average True Range (ATR)
- REGN 18.56
- MU 3.32
- MACD
- REGN -1.24
- MU -0.53
- Stochastic Oscillator
- REGN 1.89
- MU 37.88
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.